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Mechanisms contributing to atherosclerosis, the major
cause of coronary heart disease and stroke, are not well
understood. Experimental studies with cultured cells and
animal models have suggested that oxidative damage
could be an important contributing factor, but impli-
cating oxidation in human disease has proved difficult.
One potentially powerful approach is to examine poly-
morphisms of candidate genes in populations. In this
issue of the Journal, Sanghera et al. (1998) report evi-
dence that common polymorphisms in a cluster of re-
lated genes, including that for serum paraoxonase, an
enzyme of unknown function, modulate the risk for cor-
onary heart disease. A number of previous genetic epi-
demiologic studies have yielded consistent findings.
Experimental studies suggest that paraoxonase may
lower the risk for coronary heart disease by destroying
proinflammatory molecules involved in the initiation
and progression of atherosclerotic lesions; these studies
support a role for oxidative damage in the human dis-
ease. Because paraoxonase is a component of HDL, these
data provide a possible explanation for the inverse re-
lationship between HDL levels and coronary heart dis-
ease in populations. Taken together with previous stud-
ies, these data allow paraoxonase to be added to a short
list of genes that exhibit common variations influencing
heart disease. As this list grows, improved diagnosis or
even risk assessment for coronary heart disease are likely
outcomes.
Paraoxonase, an Enzyme without a Function
Paraoxonase is a serum enzyme whose precise phys-
iological role is unknown (Mackness et al. 1996). It hy-
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drolyzes many substrates—including aromatic carbox-
ylic acid—and organophosphates such as paraoxon, a
metabolic product of the widely used pesticide para-
thion. The enzyme has been studied mainly for its ability
to break down pesticides and nerve gases, such as sarin.
Because insects generally lack paraoxonase activity, they
are particularly susceptible to these compounds. The hu-
man gene for paraoxonase, PON1, is located on the long
arm of chromosome 7, at q21-q22 (Humbert et al.
1993).
The hydrolysis products of paraoxon are relatively
nontoxic, in contrast to paraoxon itself, a potent inhib-
itor of the cholinesterases that break down the neuro-
transmitter acetylcholine (Mackness et al. 1996). Thus
paraoxonase in bloodmight help prevent paraoxon from
reaching the nervous system, where the pesticide would
cause acetylcholine to accumulate at cholinergic synaptic
junctions and to overstimulate neurons.
Serum levels of paraoxonase activity vary widely
among individuals, which may partly account for dif-
ferences in susceptibility to organophosphate poisoning
(Blatter-Garin et al. 1994; Davies et al. 1996). However,
activity remains relatively constant for a given individ-
ual. The molecular basis for this difference appears to
be a polymorphism in the PON1 gene: PON1 A, an
isoform with low activity toward paraoxon (but high
activity toward certain other organophosphates), has a
glutamine at position 192, whereas the PON1 B isoform,
with high activity toward paraoxon, contains an argi-
nine at that position (Davies et al. 1996). Thus, a single
amino acid substitution that is readily detected by re-
striction-enzyme analysis results in an eightfold differ-
ence in the enzyme’s ability to hydrolyze paraoxon.
The Oxidation Hypothesis of Atherosclerosis
Human and rabbit PON1 genes exhibit a striking de-
gree of sequence similarity (86% at the nucleotide level
and 85% at the amino acid level), suggesting that para-
oxonase may play an important role in metabolism
(Hassett et al. 1991). One intriguing hypothesis is that
the enzyme may remove lipid peroxidation products
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Table 1
Association Studies between Paraoxonase-Gene Polymorphisms and
Coronary Heart Disease
Study Polymorphism (Codon) P Valuea
Sanghera et al.
1998 PON1 (912) !.0001
Sanghera et al.
1998 PON2 (311) !.005
Odawara et al.
1997 PON1 (192) .003
Suehiro et al. 1996 PON1 (192) NS
Herrmann et al.
1996 PON1 (192) NS
Garin et al. 1997 PON1 (54) .03
Antikainen et al.
1996 PON1 (192) .12
Serrato and Marian
1995 PON1 (192) .0003
Ruiz et al. 1995 PON1 (192) .03
a NS  not significant.
(Mackness et al. 1991a). Such oxidatively damagedmac-
romolecules have been implicated in aging and in dis-
eases ranging from ischemia-reperfusion injury to ar-
thritis to cancer (Ames et al. 1993).
Many lines of evidence implicate oxidized
LDL—rather than LDL itself—in atherogenesis (Berliner
and Heinecke 1996). Immunohistochemical studies with
monoclonal antibodies that specifically recognize pro-
tein-bound lipid oxidation products provide direct evi-
dence for LDL oxidation in the artery wall. Moreover,
LDL with indications of oxidative damage has been iso-
lated from human and animal atherosclerotic lesions.
Also, several chemically unrelated lipid-soluble antiox-
idants retard or inhibit atherosclerosis in hypercholes-
terolemic animals (Berliner and Heinecke 1996), and
epidemiological studies suggest that a high dietary intake
of antioxidants is associated with a decreased risk for
coronary artery disease (Steinberg 1995). Most signifi-
cantly, vitamin E prevents acute coronary events in pa-
tients with angiographically established atherosclerotic
vascular disease (Stephens et al. 1996), suggesting that
oxidative events are of central importance.
The mechanisms that promote LDL oxidation in vivo
are uncertain, though many different pathways have
been proposed on the basis of in vitro evidence. Because
plasma exhibits a powerful array of antioxidant defense
mechanisms, however, it is generally thought that LDL
oxidation takes place in the artery wall. Recent studies
have provided direct chemical evidence that reactive ni-
trogen species and products of myeloperoxidase may
contribute to the oxidative modification of arterial wall
lipids and proteins (Heinecke 1997).Metal ionsmay also
be involved late in the disease process.
In contrast to LDL, an elevated level of HDL lowers
the risk for atherosclerosis. Because in vitro studies dem-
onstrate that HDL inhibits copper-catalyzed LDL oxi-
dation (Mackness et al. 1991a), its antiatherogenic prop-
erties may relate in part to its ability to protect LDL
from atherogenic modifications. Paraoxonase activity in
human serum is strongly associated with HDL. Indeed,
it is difficult to separate the enzyme from apolipoprotein
AI, the major HDL protein, indicating that HDL carries
most of the paraoxonase in serum. Biochemical studies
indicate that specific HDL subpopulations contain the
paraoxonase protein.
In 1991, Mackness et al. (1991a) reported that par-
aoxonase inhibits the copper-catalyzed oxidation of
LDL. This provided the first molecular hypothesis for a
specific mechanism whereby HDL might affect LDL ox-
idation. Navab, Berliner, Fogelman, and coworkers sub-
sequently discovered that paraoxonase can remove ox-
idized phospholipids from LDL (Watson et al. 1995;
Navab et al. 1996, 1997). These lipids activate inflam-
matory genes and promote the adhesion of monocytes
to endothelium, a key event in monocyte recruitment
into early atherosclerotic lesions. Thus, the enzyme may
alter the risk for vascular disease by cleansing LDL of
oxidized lipids in vivo.
Paraoxonase and the Oxidation Hypothesis
The demonstration of links between paraoxonase and
LDL oxidation led to an explosion of interest in the
enzyme’s possible role in atherosclerosis. Serum paraox-
onase levels were found to be lower in patients with
familial hypercholesterolemia and diabetes; these pa-
tients are at greatly increased risk for premature ath-
erosclerotic vascular disease (Mackness et al. 1991b).
Moreover, some but not all studies have shown that
polymorphisms in the PON1 gene associate with an in-
creased risk for coronary artery disease (table 1). The
risk varies independently of traditional lipid risk factors,
such as HDL and LDL levels, suggesting that, in some
populations, additional factors may contribute to a per-
son’s risk for developing atherosclerosis.
The influence of paraoxonase on artery disease may
be studied in inbred strains of mice, which differ dra-
matically in their susceptibility to atherosclerosis. For
example, C57BL/6J (B6) mice are susceptible to diet-
induced aortic fatty streak lesions, whereas C3H/HeJ
(C3H) mice are resistant to such lesions. When the two
strains received a low-fat diet that fails to promote ath-
erosclerosis, their HDLs protected against LDL oxida-
tion in vitro (Shih et al. 1996). In contrast, HDL isolated
from susceptible B6 mice fed a high-fat, high-cholesterol
diet was unable to inhibit LDL oxidation, whereas HDL
from resistant C3H mice retained this property. More-
over, the ability of the various HDLs to prevent LDL
oxidation was strongly associated with serum levels of
paraoxonase. Also, liver levels of paraoxonase mRNA
declined when susceptible B6 mice, but not resistant
C3H mice, were subjected to the high-fat diet, indicating
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NOTE.—Reviewed in Lusis et al. (1998).
that liver levels of paraoxonase mRNA are under genetic
control. Paraoxonase mRNA levels cosegregated with
the extent of atherosclerosis in recombinant inbred
strains of mice derived from B6 and C3H mice (Shih et
al. 1996). The results of these studies, like those from
human studies, support the notion that paraoxonase
plays a role in atherogenesis.
Paraoxonase Polymorphisms Are Associated with
Coronary Heart Disease
The report by Sanghera et al. (1998) is the latest in a
series of association studies between paraoxonase-gene
polymorphisms and coronary heart disease (table 1). The
majority of these studies have revealed significant as-
sociation, though several have not. However, association
studies have a number of potential problems. For ex-
ample, population admixture can result in apparent as-
sociations that are due to differences in the frequencies
of alleles in different ethnic groups. Certain analytic pro-
cedures, such as transmission-distortion analysis, can
minimize this problem, but such methods have not yet
been applied to studies of PON1. Another problem that
has undermined confidence in association studies is the
adoption of insufficiently stringent thresholds for estab-
lishing significant findings. For example, many studies
include multiple phenotypes and group the data in var-
ious ways for analysis. When such multiple comparisons
are performed, the threshold for significance should be
adjusted, though the degree of adjustment is often com-
plex. Because relatively few association studies consider
the problem of multiple comparisons, many findings re-
ported to be significant are in fact type 1 errors. Probably
the most convincing evidence for an association is re-
producibility in separate studies and in separate
populations.
Associations between paraoxonase-gene polymor-
phisms and coronary heart disease have now been re-
peatedly reproduced (table 1), and the negative results
of two studies could be explained by such factors as
population differences, ascertainment differences, or
simply chance. The conclusion that paraoxonase-gene
expression affects the development of coronary heart
disease is supported by several lines of evidence. As dis-
cussed above, paraoxonase can destroy certain oxidized
lipids that may contribute to the inflammatory aspects
of atherosclerosis. Also, a variety of studies have sug-
gested that low paraoxonase levels are associated with
atherosclerosis, hyperlipidemia, and type 2 diabetes
(Mackness et al. 1991b, 1996; Navab et al. 1996). Fi-
nally, genetic studies of mice have revealed a relationship
between paraoxonase expression and fatty streak lesions
in mice (Shih et al. 1996).
A Cluster of Paraoxonase Genes
PON1 appears to be clustered with at least two other
closely related genes, PON2 and PON3. The latter ap-
pear to be expressed in a variety of tissues, and their
products are likely to be intracellular rather than se-
creted (Primo-Parmo et al. 1996). This raises the pos-
sibility that the associations observed for the PON1
polymorphism result from linkage disequilibrium with
a closely linked PON gene. Sanghera et al. (1998) have
explored this issue by typing a polymorphism of PON2,
as well as the 192 polymorphism of PON1. The results
indicate that both polymorphisms are significantly as-
sociated with coronary heart disease, though the PON1
association is much stronger (table 1). The data on the
distributions of genotypes at the two genes suggest an
interaction affecting the risk of coronary heart disease,
though this requires confirmation. It remains possible
that the observed association is due to linkage disequi-
librium with either PON3 or another nearby gene. Also,
since haplotypes for the PON1 and PON2 polymor-
phisms were not rigorously analyzed by use of families,
it remains possible that the PON2 association is due to
linkage disequilibrium with the PON1 polymorphism.
Toward an Understanding of the Biochemical and
Genetic Basis of Coronary Heart Disease
The study reported by Sanghera et al. (1998) has im-
portant mechanistic implications. In vitro studies suggest
that paraoxonase inhibits LDL oxidation by decompos-
ing peroxidized lipids, such as the oxygenated phospho-
lipids implicated in monocyte attachment to endothe-
lium. However, the allele most commonly associated
with an increased risk of coronary heart disease, PON1
B, elevates paraoxonase activity in plasma. Whether this
allele alters the activity of the enzyme toward the natural
substrate(s) is not yet established. Moreover, the bio-
chemical mechanisms by which the enzyme degrades ox-
idized lipids have not been clearly identified. It is intrigu-
ing, however, that Sanghera et al. find that both PON1
B and PON2*S appear to increase the risk of athero-
sclerosis. This raises the interesting possibility that the
two paraoxonase proteins act in concert to influence the
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formation of atherogenic molecules. Alternatively, this
combination of genotypes may be less effective at re-
moving oxidative damage from lipoproteins.
Another important implication of the study reported
by Sanghera et al. (1998) relates to our understanding
of the genetic contribution to coronary heart disease.
Although a number of Mendelian disorders contributing
to atherosclerosis, such as familial hypercholesterolemia,
have been characterized and are now relatively well un-
derstood, such disorders explain only a small fraction
of cases of coronary heart disease, the vast majority of
which result from the interactions of multiple genetic
and environmental factors. However, epidemiologic
studies of candidate genes are slowly adding to our un-
derstanding. The PON-locus polymorphisms should
now be added to a short list of other genes for which
there is significant evidence for contributions to common
forms of coronary heart disease (table 2). A number of
other genetic variations are very likely to affect risk, since
they influence factors such as homocysteine levels (the
methylenetetrahydrofolate reductase gene) or HDL cho-
lesterol (the hepatic lipase gene). Several very interesting
candidate genes, such as the scavenger receptors that
mediate cellular uptake of cholesterol to give rise to foam
cells, have yet to be examined. As this list grows, it may
be possible to subdivide the different forms of coronary
heart disease to tailor treatments to specific genetic de-
fects or even to predict an individual’s risk.
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